AUTH/2776/7/15 - Bristol-Myers Squibb and Pfizer/PMCPA Director v Bayer

Alleged breach of undertaking

  • Received
    30 June 2015
  • Case number
    AUTH/2776/7/15
  • Applicable Code year
    2015
  • Completed
    19 August 2015
  • No breach Clause(s)
    2, 7.2, 9.1 and 29
  • Additional sanctions
  • Appeal
    no appeal
  • Review
    November 2015

Case Summary

Bristol-Myers Squibb and Pfizer complained that a Xarelto (rivaroxaban) leavepiece entitled 'For elderly patients taking aspirin for stroke prevention ... It's time to rethink their protection' breached the undertaking given by Bayer in Case AUTH/2650/11/13. 

As the complaint was about an alleged breach of undertaking it was taken up by the Director as it was the Authority's responsibility to ensure compliance with undertakings.

The complainants referred to Case AUTH/2650/11/13 which concerned another Xarelto leavepiece and noted the Panel's view that 'although Patel et al [2011, the ROCKET AF trial] had shown that overall Xarelto had a comparable safety profile compared with warfarin, it was important for health professionals to know that patients treated with Xarelto were at increased risk of GI [gastrointestinal] bleeds vs patients on warfarin; the health professionals could thus manage that risk appropriately'. Bayer was ruled in breach of the Code.

The leavepiece now at issue profiled a patient, a 75 year old woman with non-valvular atrial fibrillation (NVAF) who was currently prescribed aspirin. The material thus unequivocally focussed on the indication of stroke prevention in NVAF. 

Bristol-Myers Squibb and Pfizer noted that a page headed 'Xarelto: Demonstrated safety profile across indications' provided the following information about the safety of Xarelto in NVAF: 

​'In patients with non-valvular AF, from the ROCKET-AF trial:

• Xarelto demonstrated a comparable safety profile vs warfarin.' 

Bristol-Myers Squibb and Pfizer stated that following this text there was no further mention of safety information from Patel et al (2011). The remainder of the page highlighted bleeding safety data from EINSTEIN which was data from a population with venous thromboembolism (VTE) not NVAF. Importantly, no secondary safety endpoints for bleeding from Patel et al had been included. GI bleeding rates for Xarelto compared with warfarin from Patel et al had been omitted. 

The complainants alleged that the page was misleading as not all key safety endpoints for Xarelto were comparable to warfarin in Patel et al. Bristol-Myers Squibb and Pfizer noted that major bleeding from GI sites occurred significantly more frequently in the rivaroxaban group than in the warfarin group; 224 bleeding events (3.2%) vs 154 bleeding events (2.2%) (p<0.001) respectively.

Furthermore Section 4.4 of the Xarelto summary of product characteristics (SPC) highlighted the difference between Xarelto and warfarin with regard to GI bleeding including:

'Haemorrhagic risk … In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary) and anaemia were seen more frequently during long-term rivaroxaban treatment compared with VKA [vitamin K antagonist] treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/ haematocrit could be of value to detect occult bleeding, as judged to be appropriate.' 

Bristol-Myers Squibb and Pfizer alleged that Bayer had failed to comply with the undertaking in Case AUTH/2650/11/13 and was in breach of various clauses of the Code including Clause 2. 

The detailed response from Bayer is given below. 

The Panel noted that an undertaking was an important document. It included an assurance that all possible steps would be taken to avoid similar breaches of the Code in future. It was very important for the reputation of the industry that companies complied with undertakings.

The Panel noted its rulings in Case AUTH/2650/11/13 related to a page headed 'A reassuring safety profile matters' and sub-headed 'Xarelto significantly reduces the risk of fatal bleeds by 50% vs warfarin in AF [atrial fibrillation]'. The page detailed safety data from Patel et al which compared Xarelto and warfarin. The page featured a bar chart above the claim 'Comparable safety profile vs warfarin with an increased risk of bleeding from GI sites'. The Panel noted that the increased risk of bleeding from GI sites had not been quantified in the same way as the decreased risk of other bleeding events had been in the bar chart (event rate, relative risk and p-values). In the Panel's view the failure to give readers the comparable data for GI bleeding was misleading and a breach had been ruled.

Turning to Case AUTH/2776/7/15, the Panel noted the page at issue was headed 'Because of Jean's age and hypertension she's at moderate risk of a major bleed' followed by 'Xarelto: Demonstrated safety profile across indications' above 'In patients with non-valvular AF, from the ROCKET-AF trial: Xarelto demonstrated a comparable safety profile vs warfarin'. The Panel noted that the claim 'Xarelto demonstrated a comparable safety profile vs warfarin' was referenced to Patel et al, rather than the ROCKET AF trial. 

​The Panel considered that there were differences between the material considered in CaseAUTH/2650/11/13 and that now at issue. The leavepiece at issue broadly compared the safety profile of Xarelto vs warfarin. The claim at issue did not mention specific bleeding sites or the risk of bleeds per se. Subsequent claims on the same page did not mention specific bleeding sites although the risk of major and non-major and clinically relevant bleeds were referred to. The material at issue in Case AUTH/2650/11/13 had, inter alia, compared certain bleeding events in a bar chart and referred in text below this bar chart to GI bleeding events. The Panel considered the claim now at issue 'In patients with non-valvular AF, from the ROCKET-AF trial: Xarelto demonstrated a comparable safety profile vs warfarin', was not sufficiently similar to that at issue in Case AUTH/2650/11/13 for it to be covered by the undertaking given in that case. Thus the Panel ruled no breach of the Code including Clause 2.​